Skip to main content
Kilitch Drugs (I) Ltd. logo

Kilitch Drugs (I) Ltd. — Investor Relations & Filings

Ticker · KILITCH ISIN · INE729D01010 BSE.NS Manufacturing
Open in API
Filings indexed 550 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country IN India
Listing BSE.NS KILITCH

About Kilitch Drugs (I) Ltd.

https://kilitch.com/

Kilitch Drugs (I) Ltd. is a pharmaceutical formulation manufacturer specializing in a diverse range of therapeutic segments. The company focuses on the development and production of sterile products, including liquid and dry powder injectables, ophthalmic preparations, and ear drops. Its product portfolio also encompasses oral solids such as tablets and capsules, as well as liquid orals. Key therapeutic areas served include anti-infectives, gastroenterology, ophthalmology, and pain management. The company operates manufacturing facilities compliant with international quality standards, providing both branded generics and contract manufacturing services. Kilitch Drugs maintains a significant presence in various international markets, leveraging its technical expertise in sterile manufacturing to deliver high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
We are hereby submitting annual secretarial compliance report for the year ended 31st March, 2026
Regulatory Filings Classification · 91% confidence The document is a detailed Annual Secretarial Compliance Report filed under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is not a financial audit report, interim or annual financial report, nor an earnings release or management discussion. It is a compliance certificate/report submitted to the stock exchanges to satisfy regulatory obligations. There is no specific category for Secretarial Compliance Reports, so under the fallback hierarchy this is classified as a general Regulatory Filing (RNS).
2026-05-27 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 73% confidence The document consists of two formal stock exchange filings by the promoters of Kilitch Drugs under Regulation 31(4) of SEBI’s Substantial Acquisition of Shares & Takeover Regulations, 2011. These are routine compliance disclosures regarding promoters’ encumbrance status and are not standalone financial reports, M&A announcements, or threshold‐crossing notifications of share ownership. Therefore, it falls under the general regulatory announcements category (RNS).
2026-05-21 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 85% confidence The document is a compliance disclosure under SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011, submitted to Indian stock exchanges confirming no encumbrances over promoter shares. It is a regulatory filing and does not report financial results, management changes, or actual share transactions. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-20 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 88% confidence The document is a brief letter to the stock exchanges notifying them that the extract of the company’s financial results (quarter and year ended March 31, 2026) has been published in newspapers and enclosing copies. It contains no substantive financial data itself and merely announces the publication of the extract. This fits the definition of a Report Publication Announcement (RPA).
2026-05-18 English
We are submitting hereby copy of newspaper publication of the extract of financial results for the quarter ended 31st March, 2026
Report Publication Announcement Classification · 85% confidence The document is a formal notice to stock exchanges attaching newspaper extracts of the company’s quarter- and year-end financial results. It does not contain the full financial statements itself but announces and submits the publication of those results in newspapers. Under the “menu vs meal” rule, this is an announcement of report publication rather than the report itself, fitting the description of a Report Publication Announcement (RPA).
2026-05-18 English
We are hereby submitting audited standalone and consolidated financial results of the Company for the quarter ended 31st March, 2026
Regulatory Filings Classification · 82% confidence The document is a formal SEBI Listing Obligations filing by Kilitch Drugs (India) Ltd. notifying stock exchanges of the Board’s approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. It includes the Independent Auditor’s Report and detailed financial statements. It is not a full Annual Report (10-K) or Management Discussion (MDA), nor an earnings highlights press release (ER) or investor presentation (IP). This is a standard regulatory compliance announcement under Listing Regulations, which does not fit into more specific categories, making “Regulatory Filings” (RNS) the appropriate classification.
2026-05-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.